← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
camrelizumab
L01FF14
Forms & Strengths
- injection 100mg/4mL
- injection 200mg/10mL
Adult Dosing
- 200mg IV q2w
- 400mg IV q6w
Indications
- reurrent or metastatic nasopharyngeal carcinoma
- advanced hepatocellular carcinoma
- ES-SCLC
Mechanism of Action
- PD-1 inhibitor
- blocks interaction with PD-L1 and PD-L2
- promotes antitumor immune response
Adverse Reactions
- fatigue
- pruritus
- rash
- diarrhea
- hepatotoxicity
- pneumonitis
- colitis
- endocrinopathies
Drug Interactions
- immunosuppressants may decrease effectiveness
Curated Content: Needs Vetting Before Put to Clinical Use